Oslo, Norway, 24 November 2009
Clavis Pharma ASA (OSE: CLAVIS), the clinical stage oncology focused pharmaceutical company, announced today a $380 million agreement for the further development and commercialisation of its drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.
A meeting for investors, analysts and press will take place in Oslo at 10.00 CET today, 24 November 2009 at Hotel Continental, Stortingsgaten 24, Oslo Norway.
An international conference call will take place at 12:00 CET - details are given below.
Access the audio for the meeting by dialling the following and quoting confirmation code 4956336 :
+47 2415 9758 (from Norway)
+44 (0)20 7806 1966 (International)
For visuals click on the direct access link:
http://www.livemeeting.com/cc/premconfeurope/join?id=4956336&role=attend&pw=pw6623
Participating in the Meeting and Conference Call will be:
Geir Christian Melen, CEO, Clavis Pharma ASA
Keith McCullagh,
Chairman, Clavis Pharma ASA
Patrick Mahaffy. President & CEO, Clovis Oncology Inc.
The presentation will be made available on www.clavispharma.com in the Investors section from 09:00 CET. A webcast of the conference call will be available from Clavis Pharma's website, www.clavispharma.com for a period of 30 days.
For Further Information Contact:
Geir Christian Melen
Chief Executive Officer
+47 24 11 09 50
+47 91 30 29 65 (mob)
geir.christian.melen@clavispharma.com
Gunnar Manum
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
gunnar.manum@clavispharma.com
Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
+44 207 282 2948
clavispharma@citigatedr.co.uk